{"id":"gp-combined-with-tislelizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Chemotherapy-related myelosuppression"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab is a humanized PD-1 inhibitor that blocks the programmed death-1 checkpoint, releasing T-cell inhibition and promoting anti-tumor immunity. The GP chemotherapy regimen (gemcitabine and cisplatin) provides direct cytotoxic activity against cancer cells. The combination leverages chemotherapy's immunogenic cell death to synergize with checkpoint inhibition for enhanced therapeutic effect.","oneSentence":"GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:15.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication under investigation in Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT06177301","phase":"PHASE3","title":"Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Nasopharyngeal Carcinoma","enrollment":266},{"nctId":"NCT04833257","phase":"PHASE2","title":"Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-04-14","conditions":"Nasopharyngeal Carcinoma","enrollment":63},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT05532059","phase":"PHASE2","title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-31","conditions":"Advanced Cholangiocarcinoma","enrollment":100},{"nctId":"NCT06536959","phase":"PHASE2","title":"VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-07-18","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":67},{"nctId":"NCT06383780","phase":"PHASE3","title":"Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-15","conditions":"Nasopharyngeal Carcinoma","enrollment":90},{"nctId":"NCT05211232","phase":"PHASE3","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-10","conditions":"Nasopharyngeal Carcinoma","enrollment":450},{"nctId":"NCT05023109","phase":"PHASE2","title":"GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-02-01","conditions":"Biliary Tract Carcinoma","enrollment":45},{"nctId":"NCT05652192","phase":"PHASE2","title":"SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-09-15","conditions":"Advanced Nasopharyngeal Carcinoma","enrollment":37},{"nctId":"NCT05448885","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-09-01","conditions":"Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT04921995","phase":"PHASE2","title":"Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-04-15","conditions":"Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect","enrollment":40},{"nctId":"NCT05019677","phase":"PHASE2","title":"GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC","status":"WITHDRAWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP combined with Tislelizumab","genericName":"GP combined with Tislelizumab","companyName":"XIANG YANQUN","companyId":"xiang-yanqun","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction. Used for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}